What is the official website of Novartis Serbia ?

The official website of Novartis Serbia is https://www.novartis.com/rs-sr/.

What is Novartis Serbia's cybersecurity risk score?

Novartis Serbia has an AI-generated cybersecurity risk score of 749 out of 1000, indicating a Moderate security posture according to Rankiteo's assessment.

How many security incidents has Novartis Serbia experienced?

According to Rankiteo, Novartis Serbia currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Serbia been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Serbia has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Serbia have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Serbia is not certified under SOC 2 Type 1.

Does Novartis Serbia have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Serbia does not hold a SOC 2 Type 2 certification.

Does Novartis Serbia comply with GDPR ?

According to Rankiteo, Novartis Serbia is not listed as GDPR compliant.

Does Novartis Serbia have PCI DSS certification ?

According to Rankiteo, Novartis Serbia does not currently maintain PCI DSS compliance.

Does Novartis Serbia comply with HIPAA ?

According to Rankiteo, Novartis Serbia is not compliant with HIPAA regulations.

Does Novartis Serbia have ISO 27001 certification ?

According to Rankiteo,Novartis Serbia is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Serbia operate in ?

Novartis Serbia operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Serbia have ?

Novartis Serbia employs approximately 2 people worldwide.

Does Novartis Serbia own any subsidiaries ?

Novartis Serbia presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Serbia have ?

Novartis Serbia's official LinkedIn profile has approximately 982 followers.

What is the NAICS classification code for Novartis Serbia ?

Novartis Serbia is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Serbia have a Crunchbase profile ?

No, Novartis Serbia does not have a profile on Crunchbase.

Does Novartis Serbia have a LinkedIn profile ?

Yes, Novartis Serbia maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartisserbia.

How many cybersecurity incidents has Novartis Serbia experienced ?

As of September 13, 2026, Rankiteo reports that Novartis Serbia has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Serbia have ?

Novartis Serbia has an estimated 5,760 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Serbia faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Serbia

Boost Score +25 with badge (5 left)

749

/1000

Moderate

774

/1000

Fair

Novartis Serbia Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis je inovativna farmaceutska kompanija. Svakodnevno radimo na tome da pronađemo i unapredimo medicinska otkrića u cilju poboljšanja kvaliteta i dužine ljudskih života, i kako bismo osnažili pacijente, zdravstvene radnike i države u borbi sa ozbiljnim oboljenjima. Preko 250 miliona ljudi širom sveta ima pristup našim lekovima. Saznajte više na http://www.novartis.com/rs-sr Molimo vas da pogledate naše smernice za korišćenje društvene mreže Linkedin: https://www.novartis.com/rs-sr/novartisove-smernice-za-drustvenu-mrezu-linkedin Ovde možete videti našu politiku zaštite privatnosti: Politika zaštite privatnosti na internet stranici: https://www.novartis.com/rs-sr/zastita-privatnosti ▪ Novartis is an innovative medicines company.

Novartis Serbia

Novartis Serbia CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Serbia

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Serbia Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Serbia

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Serbia in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Serbia in 2026.

Incident Types Novartis Serbia vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Serbia in 2026.

Incident History - Novartis Serbia (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Serbia Subsidiaries

Novartis Serbia

Pharmaceutical Manufacturing

Website: https://www.novartis.com/rs-sr/

Company Size: 2

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis MalaysiaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis EuropePharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologiePharmaceutical Manufacturing

Novartis Nederland - OncologiePharmaceutical Manufacturing

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologiePharmaceutical Manufacturing

Novartis Nederland - ReumatologiePharmaceutical Manufacturing

Novartis Nederland - Cardiovascular, Renal & MetabolismPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Loading…

Novartis Serbia Similar Companies

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

EMS

cb ems.com.br

Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Medical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Loading…

NEWS

Novartis Serbia CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-90647

SUMMARY

ASE/Kalkitech ASE2000 V2 Communication Test Set 2.35 through 2.37 on Windows contains an improper certificate validation vulnerability in the IEC 60870-5-104 TLS client (Task Mode). This allows a network-positioned attacker to bypass certificate validation via a certificate with multiple simultaneous faults, enabling a Man-in-the-Middle attack on protected communications.

Published

Date2026-09-12

Updated

Date2026-09-12

RISK INFORMATION (Score: 7.4)

cvss3

Base Score: 7.4

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:N

cvss4

Base Score: 9.1

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

2.2

REFERENCES

https://www.ase-systems.com/wp-content/uploads/2026/07/CYB_2026_86278_Advisory_v1.0.pdf

CVE-2026-90487

SUMMARY

A vulnerability was found in Xuxueli xxl-job up to 3.4.2. Affected by this issue is some unknown functionality of the file xxl-job-admin/src/main/java/com/xxl/job/admin/business/controller/JobGroupController.java. The manipulation results in improper privilege management. The attack may be launched remotely. The exploit has been made public and could be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-12

Updated

Date2026-09-12

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 4.0

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:N/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-90486

SUMMARY

A vulnerability has been found in openstatusHQ openstatus up to f04c827112f30a11d571ebdad3892826034d6265. Affected by this vulnerability is an unknown functionality of the file apps/status-page/src/lib/proxy/resolve-custom-domain-rewrite.ts. The manipulation leads to server-side request forgery. The attack may be initiated remotely. This product uses a rolling release model to deliver continuous updates. As a result, specific version information for affected or updated releases is not available. The identifier of the patch is 86f370c9c20074c3c3fdec53a359874b8e670fd4. It is suggested to install a patch to address this issue. This issue got fixed with a silent patch.

Published

Date2026-09-12

Updated

Date2026-09-12

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-79300

SUMMARY

SEP sesam before 5.2.0.24 mishandles User Authorization with MFA. If AD authentication is configured and MFA is enforced, an attacker can create a second OTP access capability. SEP sesam and Active Directory handle username capitalization differently, which may allow multiple SEP sesam user accounts to be created for the same Active Directory (AD) account. Active Directory treats usernames as case-insensitive, while SEP sesam distinguishes between different letter casing. As a result, the same AD user can be represented by multiple SEP sesam user accounts that differ only in username capitalization. When Active Directory authentication is configured and multi-factor authentication (MFA) is enforced, this behavior may allow an additional OTP Authenticator to be registered for the same AD account, reducing the effectiveness of MFA protection.

Published

Date2026-09-12

Updated

Date2026-09-12

RISK INFORMATION (Score: 3.5)

cvss3

Base Score: 3.5

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:N/I:L/A:N

Impact Score

1.4

Exploitability

1.8

REFERENCES

https://wiki.sep.de/wiki/index.php/Release_Notes_5.2.0_Artemis#fixed

CVE-2026-90485

SUMMARY

A flaw has been found in IOBit Uninstaller 15.5.0.11. Affected by this issue is the function sub_11838 of the file IURegistryFilter.sys of the component IOCTL Dispatch Handler. This manipulation causes null pointer dereference. The attack requires local access. The exploit has been published and may be used. Identical IURegistryFilter.sys ships across multiple IObit families. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-12

Updated

Date2026-09-12

RISK INFORMATION (Score: 5.5)

cvss2

Base Score: 4.6

Complexity: LOW

AV:L/AC:L/Au:S/C:N/I:N/A:C

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 5.4

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis Serbia Vendor Cyber Rating & Cyber Score

Novartis Serbia A.I CyberSecurity Scoring

Novartis Serbia CyberSecurity News & History

Novartis Serbia Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Serbia

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Serbia vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Serbia (X = Date, Y = Severity)

Novartis Serbia Subsidiaries

Novartis Serbia

Novartis Serbia Similar Companies

PT Kalbe Farma, Tbk

Alkem Laboratories Ltd.

EMS

UCB

Takeda

Lonza

Zoetis

Glenmark Pharmaceuticals

Fresenius Kabi

Novartis Serbia CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis Serbia CyberSecurity News & History

Novartis Serbia Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Serbia

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Serbia vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Serbia (X = Date, Y = Severity)

Novartis Serbia Subsidiaries

Novartis Serbia

Novartis Serbia Similar Companies

PT Kalbe Farma, Tbk

Alkem Laboratories Ltd.

EMS

UCB

Takeda

Lonza

Zoetis

Glenmark Pharmaceuticals

Fresenius Kabi

Novartis Serbia CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo